STOCK TITAN

BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call on November 1, 2022, at 8:00 a.m. CDT to review its first quarter 2023 financial results.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings date

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call on November 1, 2022, at 8:00 a.m. CDT to review its first quarter 2023 financial results. Investors can access the call via dial-in or webcast. A recorded rebroadcast will be available from 11:00 a.m. CDT on the same day until 11:00 p.m. CST on December 1, 2022. In fiscal 2022, Bio-Techne generated approximately $1.1 billion in net sales and has a diverse portfolio, including reagents, diagnostic products, and genomic tools vital for biomedical research.

Loading...
Loading translation...
Argus Session date unavailable
-3.89% session move Open Argus
Details

News Market Reaction – TECH

The recorded move for TECH in the trading session of this news was -3.89%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MINNEAPOLIS, Oct. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022, at 8:00 a.m. CDT to review first quarter 2023 financial results.

Access to the discussion may be obtained as follows:

Time:

8:00 a.m. CDT

Date:

November 1, 2022

Dial-in:

1-877-407-9208 or 1-201-493-6784 (for international callers)

Conference ID:

13733551

Webcast:

 https://viavid.webcasts.com/starthere.jsp?ei=1575794&tp_key=2a97c8f47a

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13733551.

The replay will be available from 11:00 a.m. CDT on Tuesday, November 1, 2022, until 11:00 p.m. CST on Thursday, December 1, 2022.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:

David Clair, Vice President, Investor Relations


david.clair@bio-techne.com


612-656-4416 

Bio-Techne

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-november-1-2022-to-announce-first-quarter-2023-financial-results-301643473.html

SOURCE Bio-Techne Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What date will Bio-Techne announce its first quarter 2023 financial results?

Bio-Techne will announce its first quarter 2023 financial results on November 1, 2022.

What time is the conference call for Bio-Techne's financial results?

The conference call for Bio-Techne's financial results is scheduled for 8:00 a.m. CDT on November 1, 2022.

How can I access the Bio-Techne conference call?

You can access the Bio-Techne conference call through dial-in numbers or via their webcast.

What were Bio-Techne's net sales in fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.

Will there be a recorded rebroadcast of the Bio-Techne conference call?

Yes, a recorded rebroadcast will be available from 11:00 a.m. CDT on November 1, 2022, until 11:00 p.m. CST on December 1, 2022.

Keep reading